A new RegenMed white paper (Sept 2025) argues synthetic healthcare data is being oversold for clinical validation. The headline risks: rare events get smoothed away, time-dependent signals get lost, bias can be amplified, and FDA/EMA skepticism is rising.
RegenMed: synthetic data falls short on rare events, temporal nuance, and bias
RegenMed’s September 2025 white paper flags structural limitations in synthetic healthcare datasets generated by modern models. According to the paper, generative approaches can under-represent rare clinical events and fail to preserve temporal nuance—two failure modes that matter when models are used for patient-facing decisions or safety-critical workflows.
The paper also highlights that synthetic data can amplify biases present in the source data. On the regulatory front, it notes increasing skepticism from the FDA and EMA toward synthetic-only validation for high-stakes medical devices and diagnostics, pushing teams toward hybrid evidence packages that still include real-world datasets.
- Use synthetic where it’s strongest: For dev/test, QA, and pipeline hardening, synthetic data can accelerate iteration without exposing PHI—but treat it as pre-production unless you can prove clinical-grade fidelity.
- Rare events are a known weak point: If your risk model depends on low-prevalence outcomes (adverse events, edge-case phenotypes), plan to validate on real-world cohorts and explicitly measure synthetic coverage of tails, not just averages.
- Regulators want real evidence: Teams pitching synthetic data as a substitute for clinical trials should expect pushback; positioning synthetic as supportive evidence alongside real-world validation is more aligned with FDA/EMA expectations described in the paper.
- Bias controls move from “nice to have” to gating: Privacy and compliance stakeholders should require bias audits (and documented mitigation) as part of synthetic data release criteria, since synthesis can reproduce or worsen disparities.